1
|
Brown F, Hwang I, Sloan S, Hinterschied C, Helmig‐Mason J, Long M, Youssef Y, Chan W, Prouty A, Chung J, Zhang Y, Chen‐Kiang S, DiLiberto M, Elemento O, Sehgal L, Alinari L, Scherle P, Vaddi K, Lapalombella R, Paik J, Baiocchi RA. PRMT5 INHIBITION RESTARTS A PRO‐APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL‐2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.143_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- F Brown
- The Ohio State University Department of Hematology Columbus USA
| | - I Hwang
- Weil Cornell Medicine Department of Pathology and Laboratory Medicine New York USA
| | - S Sloan
- The Ohio State University Department of Hematology Columbus USA
| | - C Hinterschied
- The Ohio State University Department of Hematology Columbus USA
| | - J Helmig‐Mason
- The Ohio State University Department of Hematology Columbus USA
| | - M Long
- The Ohio State University Department of Hematology Columbus USA
| | - Y Youssef
- The Ohio State University Department of Hematology Columbus USA
| | - W Chan
- The Ohio State University Department of Hematology Columbus USA
| | - A Prouty
- The Ohio State University Department of Hematology Columbus USA
| | - J Chung
- The Ohio State University Department of Hematology Columbus USA
| | - Y Zhang
- Prelude Therapeutics, R&D, Wilmington Delaware USA
| | - S Chen‐Kiang
- Weil Cornell Medicine Department of Pathology and Laboratory Medicine New York USA
| | - M DiLiberto
- Weil Cornell Medicine Department of Pathology and Laboratory Medicine New York USA
| | - O Elemento
- Weil Cornell Medicine Department of Physiology & Biophysics, New York New York USA
| | - L Sehgal
- The Ohio State University Department of Hematology Columbus USA
| | - L Alinari
- The Ohio State University Department of Hematology Columbus USA
| | - P Scherle
- Prelude Therapeutics, R&D, Wilmington Delaware USA
| | - K Vaddi
- Prelude Therapeutics, R&D, Wilmington Delaware USA
| | - R Lapalombella
- The Ohio State University Department of Hematology Columbus USA
| | - J Paik
- Weil Cornell Medicine Department of Pathology and Laboratory Medicine New York USA
| | - R. A Baiocchi
- The Ohio State University Department of Hematology Columbus USA
| |
Collapse
|
2
|
Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y. A SINGLE‐CENTER RETROSPECTIVE ANALYSIS OF THE TOXICITY OF HIGH‐DOSE METHOTREXATE (HDMTX) ADMINISTERED ON THE FIRST DAY OF (R)CHOP IN AGGRESSIVE NONHODGKIN LYMPHOMAS (ANHLS). Hematol Oncol 2021. [DOI: 10.1002/hon.92_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M Fleming
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - Y Huang
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - E Dotson
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - D. A Bond
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - J Reneau
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - N Epperla
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - L Alinari
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - J Brammer
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - B Christian
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - R. A Baiocchi
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - K Maddocks
- The Ohio State University Internal Medicine Columbus Ohio USA
| | - Y Sawalha
- The Ohio State University Internal Medicine Columbus Ohio USA
| |
Collapse
|
3
|
Maakaron J, Zhao Q, Puto M, Von Derau R, Robinson J, Brammer J, Penza S, Baiocchi R, Christian B, Maddocks K, Saad A, Wall S, Benson D, Efebera Y, Rosko A, Ayyappan S, Grieselhuber N, Vasu S, Larkin K, Epperla N, Devarakonda S, Choe H, Chaudhry M, Blaser B, Blachly J, Bhatnagar B, Alinari L, Mims A, Jaglowski S, William B. PHASE I DOSE-ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH-RISK NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS. Hematol Oncol 2019. [DOI: 10.1002/hon.213_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Maakaron
- Hematology; The Ohio State University; Columbus United States
| | - Q. Zhao
- Hematology; The Ohio State University; Columbus United States
| | - M. Puto
- Hematology; The Ohio State University; Columbus United States
| | - R. Von Derau
- Hematology; The Ohio State University; Columbus United States
| | - J. Robinson
- Hematology; The Ohio State University; Columbus United States
| | - J. Brammer
- Hematology; The Ohio State University; Columbus United States
| | - S. Penza
- Hematology; The Ohio State University; Columbus United States
| | - R. Baiocchi
- Hematology; The Ohio State University; Columbus United States
| | - B. Christian
- Hematology; The Ohio State University; Columbus United States
| | - K. Maddocks
- Hematology; The Ohio State University; Columbus United States
| | - A. Saad
- Hematology; The Ohio State University; Columbus United States
| | - S. Wall
- Hematology; The Ohio State University; Columbus United States
| | - D. Benson
- Hematology; The Ohio State University; Columbus United States
| | - Y. Efebera
- Hematology; The Ohio State University; Columbus United States
| | - A. Rosko
- Hematology; The Ohio State University; Columbus United States
| | - S. Ayyappan
- Hematology; The Ohio State University; Columbus United States
| | - N. Grieselhuber
- Hematology; The Ohio State University; Columbus United States
| | - S. Vasu
- Hematology; The Ohio State University; Columbus United States
| | - K. Larkin
- Hematology; The Ohio State University; Columbus United States
| | - N. Epperla
- Hematology; The Ohio State University; Columbus United States
| | - S. Devarakonda
- Hematology; The Ohio State University; Columbus United States
| | - H. Choe
- Hematology; The Ohio State University; Columbus United States
| | - M. Chaudhry
- Hematology; The Ohio State University; Columbus United States
| | - B. Blaser
- Hematology; The Ohio State University; Columbus United States
| | - J. Blachly
- Hematology; The Ohio State University; Columbus United States
| | - B. Bhatnagar
- Hematology; The Ohio State University; Columbus United States
| | - L. Alinari
- Hematology; The Ohio State University; Columbus United States
| | - A. Mims
- Hematology; The Ohio State University; Columbus United States
| | - S. Jaglowski
- Hematology; The Ohio State University; Columbus United States
| | - B.M. William
- Hematology; The Ohio State University; Columbus United States
| |
Collapse
|
4
|
William B, Abbasi A, Huang Y, Larbi R, Giali R, Yang L, Brammer J, Grantier C, Hoffman C, Ayyappan S, Baiocchi R, Epperla N, Christian B, Alinari L, Maddocks K, Chung C. A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMIDE (LEN) IN RELAPSED AND REFRACTORY (R/R) CUTANEOUS (CTCL) AND PERIPHERAL (PTCL) T-CELL LYMPHOMAS: PRELIMINARY RESULTS OF A PHASE II TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.150_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- B.M. William
- Hematology; The Ohio State University; Columbus United States
| | - A. Abbasi
- Hematology; The Ohio State University; Columbus United States
| | - Y. Huang
- Hematology; The Ohio State University; Columbus United States
| | - R. Larbi
- Hematology; The Ohio State University; Columbus United States
| | - R. Giali
- Hematology; The Ohio State University; Columbus United States
| | - L. Yang
- Hematology; The Ohio State University; Columbus United States
| | - J. Brammer
- Hematology; The Ohio State University; Columbus United States
| | - C. Grantier
- Hematology; The Ohio State University; Columbus United States
| | - C. Hoffman
- Hematology; The Ohio State University; Columbus United States
| | - S. Ayyappan
- Hematology; The Ohio State University; Columbus United States
| | - R. Baiocchi
- Hematology; The Ohio State University; Columbus United States
| | - N. Epperla
- Hematology; The Ohio State University; Columbus United States
| | - B. Christian
- Hematology; The Ohio State University; Columbus United States
| | - L. Alinari
- Hematology; The Ohio State University; Columbus United States
| | - K. Maddocks
- Hematology; The Ohio State University; Columbus United States
| | - C. Chung
- Dermatology; The Ohio State University; Columbus United States
| |
Collapse
|
5
|
Alinari L, Quinion C, Blum KA. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas. Clin Pharmacol Ther 2015; 97:469-77. [PMID: 25670208 DOI: 10.1002/cpt.65] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2014] [Revised: 12/01/2014] [Accepted: 12/08/2014] [Indexed: 02/06/2023]
Abstract
The B-cell receptor pathway (BCR) is aberrantly activated in select B-cell malignancies. This knowledge has allowed for the development of inhibitors of different crucial steps of this pathway. Bruton's tyrosine kinase (BTK) is a key component of BCR signaling and functions as an important regulator of multiple cell functions including differentiation, proliferation, and survival in various B-cell malignancies. Ibrutinib is a potent, selective BTK inhibitor that has shown significant activity in specific subtypes of B-cell non-Hodgkin's lymphomas (NHLs). Given the high response rates, tolerability, and acceptable toxicities, ibrutinib was recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed mantle cell lymphoma and chronic lymphocytic leukemia. It is also currently being evaluated in combination with chemotherapy and as frontline therapy in B-cell NHL. This review summarizes the preclinical and clinical development of ibrutinib in the treatment of B-cell NHL.
Collapse
Affiliation(s)
- L Alinari
- Department of Hematology, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | | | | |
Collapse
|
6
|
Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Bacci F, Pileri S, Baccarani M. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008; 19:769-73. [PMID: 18303033 DOI: 10.1093/annonc/mdm560] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. PATIENTS AND METHODS From February 2005 to April 2006, in our institute we treated 20 eligible elderly (age > or =60 years) patients with previously untreated DLBCL using a novel regimen consisting of six cycles of CHOP chemotherapy followed 6-10 weeks later by (90)Y ibritumomab tiuxetan. RESULTS The overall response rate to the entire treatment regimen was 100%, including 95% complete remission (CR) and 5% partial remission. Four (80%) of the five patients who achieved less than a CR with CHOP improved their remission status after radioimmunotherapy. With a median follow-up of 15 months, the 2-year progression-free survival was estimated to be 75%, with a 2-year overall survival of 95%. The (90)Y ibritumomab tiuxetan toxicity included grade > or =3 hematologic toxicity in 12 of 20 patients; the most common grade > or =3 toxic effects were neutropenia (12 patients) and thrombocytopenia (7 patients). Transfusions of red blood cells and/or platelets were given to one patient. CONCLUSION This study has established the feasibility, tolerability, and efficacy of this regimen for elderly patients with DLBCL.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology and Medical Oncology 'L. & A. Seràgnoli', University of Bologna, Bologna, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
Alemtuzumab (Campath-1H) is a humanized IgG1 monoclonal antibody that targets the human CD52 antigen. CD52 is expressed by a variety of lymphoid neoplasms and most human mononuclear cell subsets. In 2001, alemtuzumab was approved for marketing in the United States and Europe for use in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). In heavily pretreated patients with CLL, the overall response rate (ORR) is approximately 35%, and in previously untreated patients the ORR is greater than 80%, with a recent randomized study suggesting it is superior to alkylator-based therapy. Importantly, alemtuzumab is effective in patients with high-risk del(17p13.1) and del(11q22.3) CLL. Alemtuzumab combination studies with fludarabine and/or monoclonal antibodies such as rituximab have demonstrated promising results. Alemtuzumab is also being studied in CLL patients as consolidation therapy for treatment of minimal residual disease, in preparation for stem cell transplantation and to prevent acute and chronic graft versus host disease. Alemtuzumab is frequently associated with acute 'first-dose' reactions when administered intravenously, but is much better tolerated when administered subcutaneously without loss of therapeutic efficacy. Additional potential adverse events associated with alemtuzumab administration include myelosuppression as well as profound cellular immune dysfunction with the associated risk of viral reactivation and other opportunistic infections. Additional studies detailing the mechanism of action of alemtuzumab as well as new strategies for prevention of opportunistic infections will aid in the future therapeutic development of this agent.
Collapse
MESH Headings
- Alemtuzumab
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm/administration & dosage
- Antibodies, Neoplasm/adverse effects
- Antibodies, Neoplasm/immunology
- Antibodies, Neoplasm/therapeutic use
- Antigens, CD/immunology
- Antigens, Neoplasm/immunology
- CD52 Antigen
- Cyclophosphamide/therapeutic use
- Glycoproteins/immunology
- Humans
- Immunotherapy
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Vidarabine/analogs & derivatives
- Vidarabine/therapeutic use
Collapse
Affiliation(s)
- L Alinari
- Division of Hematology-Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
| | | | | | | | | | | |
Collapse
|
8
|
Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, Stefoni V, Castellucci P, Fina M, Farshad M, Pileri S, Baccarani M. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17:1296-300. [PMID: 16766583 DOI: 10.1093/annonc/mdl122] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. PATIENTS AND METHODS Between June 2003-September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles. RESULTS After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET- during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment. CONCLUSIONS The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, and Nuclear Medicine, S'Orsola Hospital, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Zinzani PL, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, Alinari L, Farsad M, Musuraca G, Gabriele A, Marchi E, Nanni C, Canini R, Monetti N, Baccarani M. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91:850-4. [PMID: 15266320 PMCID: PMC2409876 DOI: 10.1038/sj.bjc.6602040] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
An extensive analysis of the reliability of positron emission tomography (PET) after induction treatment in patients with Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL). In all, 75 untreated patients with HD (n=41) or aggressive NHL (n=34) were studied with both PET and CT scans following standard chemotherapy induction therapy (ABVD or MACOP-B) with/without radiotherapy. Histopathological analysis was performed when considered necessary. After treatment, four out of five (80%) patients who were PET+/CT− relapsed, as compared with zero out of 29 patients in the PET−/CT− subset. Among the 41 CT+ patients, 10 out of 11 (91%) who were PET+ relapsed, as compared with 0 out of 30 who were PET−. The actuarial relapse-free survival (RFS) rates were 9 and 100% in the PET+ and PET− subsets, respectively (P=0.00001). All five patients who were PET+/CT− underwent a lymph node biopsy: in four (80%) cases, persistent lymphoma and was confirmed at histopathological examination. Two HD patients who were PET−/CT+ (with large residual masses in the mediastinum or lung) were submitted to biopsy, which in both cases revealed only fibrosis. In HD and aggressive NHL patients, PET positivity after induction treatment is highly predictive for the presence of residual disease, with significant differences being observable in terms of RFS. PET negativity at restaging strongly suggests the absence of active disease; histopathological verification is important in patients who show PET positivity.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology and Medical Oncology 'Seràgnoli', University of Bologna, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002; 13:1364-9. [PMID: 12196361 DOI: 10.1093/annonc/mdf208] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Among the third-generation chemotherapy regimens specifically adapted in the last decade for elderly aggressive non-Hodgkin's lymphoma (NHL) patients, we designed an 8-week cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin and prednisone (VNCOP-B) plus granulocyte colony-stimulating factor (G-CSF) regimen which, in a national multicenter trial, induced good complete response (CR) and relapse-free survival rates with only moderate toxic effects. Here we report a prospective, multicenter, randomized trial comparing the efficacy and toxicity of 8- and 12-week regimens of VNCOP-B plus G-CSF. PATIENTS AND METHODS From February 1996 to June 2001, 306 consecutive previously untreated stage II-IV aggressive NHL patients > or =60 years of age were enrolled from 12 Italian cooperative institutions. Of the 297 evaluable patients, 149 and 148 received 8- and 12-week regimens, respectively, of VNCOP-B. RESULTS The CR rates were 63% and 56% in the 8- and 12-week groups; at a median of 32 months (range 3-62 months), relapse-free survival rates were 59% and 55%, respectively. Hematological and non-hematological toxicities were similar in both treatment groups. CONCLUSIONS Our data show that extending induction treatment with the VNCOP-B plus G-CSF regimen from 8 to 12 weeks does not raise the CR rate or provide a more durable remission.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology 'Seràgnoli', University of Bologna, Bologna.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Zinzani PL, Chierichetti F, Zompatori M, Tani M, Stefoni V, Garraffa G, Albertini P, Alinari L, Ferlin G, Baccarani M, Tura S. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 2002; 43:1239-43. [PMID: 12152991 DOI: 10.1080/10428190290021704] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
For abdominal lymphoma patients, fluorine-18 fluorodeoxyglucose positron emission tomography (PET) provides unique information on the presence of residual active disease. We provide an update on the largest reported cohort of patients whose management following induction therapy was based on routine PET and computed tomography (CT) restaging. Fifty-nine patients with Hodgkin's disease or aggressive non-Hodgkin's lymphoma presenting abdominal involvement (35% with bulky disease) were studied with both PET and CT following combined chemotherapy/radiation treatment. After treatment, 3/3 (100%) patients who were PET+/CT- relapsed, compared with 0/7 patients in the PET-/CT- subset. Among the 49 patients who were CT+, six of the 10 (60%) who were PET+ relapsed, as compared with only two of the 39 (5%) who were PET-. The actuarial relapse-free survival (RFS) rates were 0 and 100% in the PET+/CT- and PET-/CT- subsets, respectively. In the PET+/CT+ subset, RFS was 94% at 5 years. PET restaging is very valuable for the identification of patients who would need appropriate second-line therapy because of the presence of residual active abdominal disease and should be made widely available in combination with CT.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Zinzani PL, Stefoni V, Tani M, Barbieri E, Albertini P, Vigna E, Gherlinzoni F, Alinari L, Galuppi A, Pileri S, Babini L, Tura S. MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results. Leuk Lymphoma 2001; 42:989-95. [PMID: 11697654 DOI: 10.3109/10428190109097718] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
A single-center, retrospective study was conducted to evaluate therapeutic results of the MACOP-B third-generation chemotherapy regimen followed by involved-field radiation therapy in a stage I-II aggressive non-Hodgkin's lymphoma (NHL) patients. From 1986 to 1995, 118 consecutive patients with the diagnosis of aggressive NHL, stage I-IE or II-IIE, with or without bulky disease were treated with MACOP-B regimen followed, when appropriate, by 30-36 Gy involved-field radiation therapy. The complete response (CR) rate was 95% after the combined modality treatment (97% for stage I-IE and 93% for stage II-IIE). Patients with bulky disease had a CR rate of 92%. Treatment was well tolerated and no deaths occurred from acute toxicity. After a median follow-up of 68 months, 24 (21%) patients relapsed. The 14-year projected relapse-free and overall survival rates were 78% and d 69%, respectively. MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Zinzani PL, Tani M, Stefoni V, Albertini P, Bendandi M, Gherlinzoni F, Alinari L, Vigna E, Tura S. Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2001; 86:287-90. [PMID: 11255276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
BACKGROUND AND OBJECTIVES To assess the efficacy and toxic profile of the NAEPP protocol, a regimen including vinorelbine, epirubicin and prednisone, in a particularly troublesome subset of patients: pretreated elderly patients with aggressive non-Hodgkin's lymphoma (NHL). DESIGN AND METHODS From November 1998 to January 2000, 20 pretreated patients who had all relapsed after first-line VNCOP-B chemotherapy were enrolled in a phase II trial and treated with the NAEPP regimen: vinorelbine (25 mg/m(2) i.v. on days 1 and 8), epirubicin (40 mg/m(2) i.v. on days 1 and 8), and prednisone (40 mg/m(2) on days 1 and 8) with granulocyte colony-stimulating factor administered at 5 mg/kg/day on days 2-5 and days 9-12. Chemotherapy was repeated every 4 weeks for a total of 6 cycles. RESULTS Six (30%) patients achieved complete remission (CR) and 7 (35%) had partial responses (PR), giving an overall response rate of 65%. The response rate was not affected either by type of relapse presentation (nodal versus nodal plus extranodal), presence of bulky disease, or time of relapse. No major toxic effects were recorded. INTERPRETATION AND CONCLUSIONS These preliminary data suggest that the NAEPP regimen is an effective combination with a low toxicity profile in elderly pretreated patients with aggressive NHL. Further trials using NAEPP as a consolidation phase following first-line treatment are needed to establish the advantage in terms of CR rate and relapse-free survival in these patients.
Collapse
Affiliation(s)
- P L Zinzani
- Istituto di Ematologia e Oncologia Medica "Seràgnoli", Policlinico S.Orsola, via Massarenti 9, 40121 Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Busutti L, Blotta A, Alinari L, Monetti N, degli Uberli E, Eusebi V. 21 Morbidity in patients (PTS) treated with 131 I metabolic therapy and external beam radiotherapy (EBRT) after thyroidectomy for differentiated carcinoma of thyroid. Second part: late toxicity. Radiother Oncol 2000. [DOI: 10.1016/s0167-8140(00)80020-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Busutti L, Alinari L, Bellanova B, degli Uberti E, Eusebi V. 45 Morbidity in patients (pts) treated with 1131 metabolic therapy and external beam radiotherapy (ebrt) after thyroidectomy for thyroid differentiated carcinoma. First part: acute toxicity. Radiother Oncol 2000. [DOI: 10.1016/s0167-8140(00)80044-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|